EMA Authorised: Mepsevii (vestronidase alfa) — Ultragenyx Germany GmbH

View source ↗

Summary

EMA authorises Mepsevii (vestronidase alfa) for mucopolysaccharidosis VII in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucopolysaccharidosis Vii

Drugs mentioned

• Mepsevii (vestronidase alfa)

Snippet

Status: Authorised. Therapeutic area: Mucopolysaccharidosis VII. MAH: Ultragenyx Germany GmbH. Decision date: 08/07/2026. Orphan medicine